Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Kd5513on Jan 21, 2022 10:30am
232 Views
Post# 34342080

Change of approach NEEDED

Change of approach NEEDED
Hopefully PL is not a Biden fan and thinks he has done amazing things and no one appreciates them and doubles down on his approach. He needs to read the tea leaves and change his approach or there will be some major selling shedding of shares to reduce risk while the mkt is correcting.

We need to get past the smile-o-meter guessing game and they need to start sharing substanative PR's Even if setting the scene of delay....... at least its known then.

Extremely sad the corp presentation was taken down for months then uploaded with a date change and not much else. This is basic stuff, and they're getting paid handsomely.

I fear another garbage offereing that will blindside us again; they dont care if they take the top off a $25 stock and knock it to $15 with dilution, they still make 5X their money on grants.
<< Previous
Bullboard Posts
Next >>